{"transactions":[{"id":727841,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":281162,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"Held by Medicxi Secondary Co-Invest I LP, a Jersey limited partnership (\"Medicxi Secondary Co-Invest I\"). MSI GP is the sole managing general partner of Medicxi Secondary Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Secondary Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Secondary Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":727840,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":11197303,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"Held by Medicxi Secondary I LP, a Jersey limited partnership (\"Medicxi Secondary I\"). Medicxi Secondary I GP Limited, a Jersey limited liability company (\"MSI GP\"), is the sole managing general partner of Medicxi Secondary I, and Medicxi Manager is the sole manager of Medicxi Secondary I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Secondary I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":727839,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":93526,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership (\"Medicxi Growth Co-Invest I\"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":727838,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":3936970,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"Held by Medicxi Growth I LP, a Jersey limited partnership (\"Medicxi Growth I\"). Medicxi Growth I GP Limited, a Jersey limited liability company (\"MGI GP\"), is the sole managing general partner of Medicxi Growth I, and Medicxi Manager is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":727837,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":55677,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"Held by Medicxi Co-Invest I LP, a Jersey limited partnership (\"Medicxi Co-Invest I\"). MVI GP is the sole managing general partner of Medicxi Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":727836,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35697,"kind":"organization","name":"Medicxi Ventures I LP","position":2,"cik":"0001760412","reported_name":"Medicxi Ventures I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35698,"kind":"organization","name":"Medicxi Co-Invest I LP","position":3,"cik":"0001760413","reported_name":"Medicxi Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35699,"kind":"organization","name":"Medicxi Ventures I GP Ltd","position":4,"cik":"0001760411","reported_name":"Medicxi Ventures I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35700,"kind":"organization","name":"Medicxi Growth I LP","position":5,"cik":"0001690310","reported_name":"Medicxi Growth I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35701,"kind":"organization","name":"Medicxi Growth Co-Invest I LP","position":6,"cik":"0001715578","reported_name":"Medicxi Growth Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35702,"kind":"organization","name":"Medicxi Growth I GP Ltd","position":7,"cik":"0001715600","reported_name":"Medicxi Growth I GP Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":8,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":9,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":10,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-24T20:26:57.000Z","date":"2026-06-24","kind":"sale","planned":false,"acquired":false,"shares":4398519,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 24, 2026, Eli Lilly and Company (\"Parent\"), through its wholly owned subsidiary LDH XV Corporation (\"Purchaser\"), acquired all outstanding Ordinary Shares of Centessa Pharmaceuticals plc (the \"Company\") by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the \"Scheme of Arrangement\"), pursuant to the Transaction Agreement dated as of March 31, 2026, by and among the Company, Parent and Purchaser (the \"Transaction Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"kind","element":"transactionCoding","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the effective time of the Scheme of Arrangement (the \"Effective Time\"), holders of Ordinary Shares became entitled to receive (a) $38.00 in cash per Ordinary Share (the \"Cash Consideration\"), without interest and less any applicable withholding taxes, and (b) one non-transferable contingent value right (a \"CVR\") entitling the holders to receive contingent payments of up to an aggregate of $9.00 per Ordinary Share, without interest and less any applicable withholding taxes, contingent upon the achievement of specified milestones set forth in the Contingent Value Rights Agreement between Parent, Purchaser and a rights agent mutually agreeable to the Company and Parent. Because each ADS represents one Ordinary Share, holders of ADSs became entitled to the same per-share consideration of $38.00 in cash plus one CVR per ADS."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(continued from footnote 3) The transfer of Ordinary Shares occurred automatically at the Effective Time pursuant to the Scheme of Arrangement, without any action by or discretion of the Reporting Persons."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Held by Medicxi Ventures I LP, a Jersey limited partnership (\"Medicxi Ventures I\"). Medicxi Ventures I GP Limited, a Jersey limited liability company (\"MVI GP\"), is the sole managing general partner of Medicxi Ventures I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\"), is the sole manager of Medicxi Ventures I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Ventures I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001193125-26-281115","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000119312526281115/ownership.xml","form_type":"4"}},{"id":2320226,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":2,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":3,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":4,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2022-03-23T20:15:20.000Z","date":"2022-03-21","kind":"other","acquired":true,"shares":45054,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents ADSs received by the reporting persons, for no consideration, pursuant to contingent value rights granted to the Reporting Persons in January 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents ADSs received by the reporting persons, for no consideration, pursuant to contingent value rights granted to the Reporting Persons in January 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"Held by Medicxi Secondary Co-Invest I LP, a Jersey limited partnership (\"Medicxi Secondary Co-Invest I\").  MSI GP is the sole managing general partner of Medicxi Secondary Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Secondary Co-Invest I.  The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Secondary Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":281162,"source":{"system":"sec-edgar","filing":"0000899243-22-011938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000089924322011938/doc4.xml","form_type":"4"}},{"id":2320225,"issuer":{"id":35581,"kind":"organization","name":"Centessa Pharmaceuticals plc","symbol":"CNTA"},"owners":[{"id":35696,"kind":"organization","name":"Medicxi Ventures Management (Jersey) Ltd","position":1,"cik":"0001715579","reported_name":"Medicxi Ventures Management (Jersey) Ltd","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35703,"kind":"organization","name":"Medicxi Secondary I LP","position":2,"cik":"0001824997","reported_name":"Medicxi Secondary I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35704,"kind":"organization","name":"Medicxi Secondary Co-Invest I LP","position":3,"cik":"0001865493","reported_name":"Medicxi Secondary Co-Invest I LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":35705,"kind":"organization","name":"Medicxi Secondary I GP Ltd.","position":4,"cik":"0001865487","reported_name":"Medicxi Secondary I GP Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Ordinary Shares","published_at":"2022-03-23T20:15:20.000Z","date":"2022-03-21","kind":"other","acquired":true,"shares":1794211,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The Ordinary Shares may be represented by American Depositary Shares (\"ADSs\"), each of which currently represents one Ordinary Share."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents ADSs received by the reporting persons, for no consideration, pursuant to contingent value rights granted to the Reporting Persons in January 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents ADSs received by the reporting persons, for no consideration, pursuant to contingent value rights granted to the Reporting Persons in January 2021."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Held by Medicxi Secondary I LP, a Jersey limited partnership (\"Medicxi Secondary I\").  Medicxi Secondary I GP Limited, a Jersey limited liability company (\"MSI GP\"), is the sole managing general partner of Medicxi Secondary I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company (\"Medicxi Manager\") is the sole manager of Medicxi Secondary I.  The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Secondary I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose."}],"balance_after":11197303,"source":{"system":"sec-edgar","filing":"0000899243-22-011938","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1865493/000089924322011938/doc4.xml","form_type":"4"}}]}